The Announcement of Resolutions of 2022 Annual
General Shareholders' Meeting(Add any other proposals)
Date of events
2022/06/17
To which item it meets
paragraph 18
Statement
1.Date of the shareholders meeting:2022/06/17
2.Important resolutions (1)Profit distribution/ deficit
compensation:Acknowledgment of 2021 loss make-up
3.Important resolutions (2)Amendments to the corporate charter:
Approved the amendment to the"Memorandum and Articles of Association."
of the Company.
4.Important resolutions (3)Business report and financial statements:
Approved the 2021 Business Report and Consolidated Financial Report
5.Important resolutions (4)Elections for board of directors and
supervisors:
Approve of by-election for one independent director.
6.Important resolutions (5)Any other proposals:
(1)Approved the amendment to the "Procedures for the Acquisition
or Disposal of Assets" of the Company.
(2)Approved the amendment to the Rules of Procedure for Shareholders'
Meeting of the Company.
(3)Approved to release the prohibition on new Independent Director from
participation in competitive business.
(4)Approve the issuance of 2022 Employees' Restricted Share Awards.
(5)Approved to release the prohibition on Director from participation
in competitive business.
7.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
Tanvex Biopharma Inc. published this content on 17 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 June 2022 11:52:06 UTC.
Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Companyâs product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.
TANVEX BIOPHARMA, INC. 
